In vitro anticancer activity of doxorubicin-loaded gelatin-coated magnetic iron oxide nanoparticles.

Magnetic drug targeting allows accumulation of drug at a defined target site with the help of an external magnetic field. Current research explored uptake and anticancer activity of doxorubicin-loaded gelatin-coated magnetic iron oxide particles (DXR-GIOPs) in order to investigate potential of gelatin-coated iron oxide particles (GIOPs) as a drug carrier in the field of magnetic drug targeting. The in vitro test was done using HeLa cells as a model cell and DXR as a model drug. The cytotoxicity and uptake of GIOPs were also studied and results were compared with that of DXR-GIOPs. The results indicated that GIOPs were not toxic to HeLa cells even at higher concentration of 1.2 mg/mL; however, DXR-GIOPs showed toxicity in time as well as dose-dependent manner. Furthermore, quantitative and qualitative uptake studies showed higher uptake of DXR-GIOPs compared to GIOPs in the identical condition by the cells.

N-hexanoyl chitosan stabilized magnetic nanoparticles: Implication for cellular labeling and magnetic resonance imaging.

This project involved the synthesis of N-hexanoyl chitosan or simply modified chitosan (MC) stabilized iron oxide nanoparticles (MC-IOPs) and the biological evaluation of MC-IOPs. IOPs containing MC were prepared using conventional methods, and the extent of cell uptake was evaluated using mouse macrophages cell line (RAW cells). MC-IOPs were found to rapidly associate with the RAW cells, and saturation was typically reached within the 24 h of incubation at 37 degrees C. Nearly 8.53 +/- 0.31 pg iron/cell were bound or internalized at saturation. From these results, we conclude that MC-IOPs effectively deliver into RAW cells in vitro and we also hope MC-IOPs can be used for MRI enhancing agents in biomedical fields.